Researchers pinpoint gene in 70% of PCa cases
A gene that has been discovered activated in a majority of breast cancer cases has been found activated in 70% of prostate cancer tumors, report scientists at the George Washington University Medical Center, Washington.
A gene that has been discovered activated in a majority of breast cancer cases has been found activated in 70% of prostate cancer tumors, report scientists at the George Washington University Medical Center, Washington.
Lead author Patricia Berg, PhD, and colleagues, found significant immunoreactivity of the BP1 was identified in approximately 70% of prostatic adenocarcinomas, whether the analysis was performed on tissue sections (50 cases) or tissue microarray platforms (123 cases). The findings compare to less than 5% BP1 activity in normal cells, according to the researchers, whose data will be published in Modern Pathology.
“BP1 is a new, potentially significant target for therapy,” Dr. Berg said. “It could be an important new diagnostic marker for prostate cancer and the other cancers in which it is expressed.”
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
